Premium
Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease
Author(s) -
Lee ShouDong,
Chan ChoYu,
Yu MayIng,
Wang YuanJen,
Chang FullYoung,
Lo KwangJuei,
Safary Assad
Publication year - 1997
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/(sici)1096-9071(199706)52:2<215::aid-jmv16>3.0.co;2-j
Subject(s) - hepatitis a vaccine , medicine , immunogenicity , seroconversion , vaccination , hepatitis a , booster dose , chronic liver disease , virology , immunology , titer , viral disease , liver disease , antibody , hepatitis , virus , gastroenterology , cirrhosis
The safety and immunogenicity of inactivated hepatitis A vaccine was evaluated in patients with chronic liver disease. Sixty hepatitis A virus antibody (anti‐HAV) seronegative patients A virus antibody (anti‐HAV) seronegative patients with chronic liver disease (56 chronic hepatitis B and four chronic hepatitis C) and from 17 to 47 years of age received a dose of 1440 ELISA units of the inactivated hepatitis A vaccine at month 0, and a booster at month 6. Anti‐HAV seroconversion (⩾ 33 mlU/mL) was 57.6% (34/59) on day 15, and reached 93.2% (55/59) 1 month after primary vaccination. At month 6, the seropositivity of anti‐HAV decreased before the booster to 69.0% (40/58). All vaccinees had measurable titers of anti‐HAV 1 month after booster vaccination, and were still seropositive at month 12. After initial vaccination, the geometric mean titers of anti‐HAV among vaccine responders were 158, 264, 74, 1309, and 409 mlU/ml at day 15 and months 1, 6, 7, and 12. Overall, 59.7% (71/119) of the vaccine doses administered were followed by mostly minor reactions. The majority of symptoms reported were local, all of which resolved within 3 days after vaccination. No significant changes in serum liver enzyme levels were detected after vaccination. Thus, an inactivated hepatitis A vaccine was safe in patients with chronic liver disease while the immune response was inferior to that observed in healthy subjects reported in a previous study. J. Med. Virol. 52:215–218, 1997. © 1997 Wiley‐Liss, Inc.